Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Requena G, Ma L, Sturmer T, Layton JB, DiBello J. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Invest. 2020 Aug;40:747-54. doi: 10.1007/s40261-020-00935-1
Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8
McKenna SP, Doward LC, Davey KM. The development and psychometric properties of the MSQOL: a migraine-specific quality-of-life instrument. Clin Drug Invest. 1998;15(5):413-23.